Literature DB >> 21162835

[Study on the prevalence of metabolic syndrome among the Kazakh population in Xinjiang].

Heng Guo1, Shu-xia Guo, Jing-yu Zhang, Ru-lin Ma, Dong-sheng Rui, Shang-zhi Xu, Feng Sun, Ao-rong Hu, Zhi-ming Yang.   

Abstract

OBJECTIVE: To analyze the prevalence of metabolic syndrome (MS) in Kazakh population, using the NCEP-ATPIII, CDS, IDF MS standards.
METHODS: Questionnaire-based survey, physical examination and blood testing were conducted according to cluster random samplings in Kazakh residents in Xinjiang. 2745 samples were collected and diagnosed by NCEP-ATPIII, CDS, IDF standards to analyze the prevalence, with the distribution of its main components of MS, among the Kazakhs population.
RESULTS: The prevalence rates of MS diagnosed by NCEP-ATPIII, CDS, IDF standards were 18.5%, 14.2% and 26.6%, while they became 14.2%, 10.9% and 20.1% after standardized by age. The prevalence of MS diagnosed by NCEP-ATPIII and IDF standard in males were higher than in females, while CDS was in the opposite situation. The prevalence of MS by these three standards increased with age. Among all the main components of MS diagnosed after these three standardization process, the prevalence of obesity, blood pressure rising and the abnormity of HDL-C were rather high. The prevalence of MS main components ≥ 1, ≥ 2, ≥ 3, ≥ 4, 5 ranked the highest compared to the lowest as to the IDF, ATPIII' and CDS diagnostic. standards
CONCLUSION: The prevalence rates and gender distribution of MS diagnosed by different standards among Kazakhs were different. The prevalence of IDF standard was the highest, with the IDF standard better than the others in early identifying the risk factors of cardiovascular disease.

Entities:  

Mesh:

Year:  2010        PMID: 21162835

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  6 in total

1.  Comparison Study of Metabolic Syndrome's Differences and Diagnostic Criteria's Applicability among Xingjiang Uighur, Kazak and Han Population.

Authors:  Sheng Jiang; Zijing Xie
Journal:  Int J Endocrinol       Date:  2012-09-10       Impact factor: 3.257

2.  Association of Serum Free Fatty Acids with Hypertension and Insulin Resistance among Rural Uyghur Adults in Far Western China.

Authors:  Shu-Xia Guo; Yi-Zhong Yan; La-Ti Mu; Qiang Niu; Jia He; Jia-Ming Liu; Shu-Gang Li; Jing-Yu Zhang; Heng Guo; Dong-Sheng Rui
Journal:  Int J Environ Res Public Health       Date:  2015-06-09       Impact factor: 3.390

3.  Comparison Between Metabolic Syndrome and the Framingham Risk Score as Predictors of Cardiovascular Diseases Among Kazakhs in Xinjiang.

Authors:  Wenwen Yang; Rulin Ma; Xianghui Zhang; Heng Guo; Jia He; Lei Mao; Lati Mu; Yunhua Hu; Yizhong Yan; Jiaming Liu; Jiaolong Ma; Shugang Li; Yusong Ding; Mei Zhang; Jingyu Zhang; Shuxia Guo
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

4.  Impact of interactions among metabolic syndrome components on the development of cardiovascular disease among Kazakhs in Xinjiang.

Authors:  Wenwen Yang; Xiang Gao; Xianghui Zhang; Yunhua Hu; Heng Guo; Kui Wang; Yizhong Yan; Jia He; Jingyu Zhang; Jiaolong Ma; Lei Mao; Lati Mu; Jiaming Liu; Shugang Li; Yusong Ding; Mei Zhang; Rulin Ma; Shuxia Guo
Journal:  PLoS One       Date:  2018-10-16       Impact factor: 3.240

5.  Association of Inflammation with Metabolic Syndrome among Low-Income Rural Kazakh and Uyghur Adults in Far Western China.

Authors:  Yi-Zhong Yan; Ru-Lin Ma; Yu-Song Ding; Heng Guo; Jing-Yu Zhang; La-Ti Mu; Mei Zhang; Jia-Ming Liu; Dong-Sheng Rui; Jia He; Feng Sun; Kui Wang; Shu-Xia Guo
Journal:  Mediators Inflamm       Date:  2015-07-01       Impact factor: 4.711

6.  Comparison of Anthropometric and Atherogenic Indices as Screening Tools of Metabolic Syndrome in the Kazakh Adult Population in Xinjiang.

Authors:  Xiang-Hui Zhang; Mei Zhang; Jia He; Yi-Zhong Yan; Jiao-Long Ma; Kui Wang; Ru-Lin Ma; Heng Guo; La-Ti Mu; Yu-Song Ding; Jing-Yu Zhang; Jia-Ming Liu; Shu-Gang Li; Qiang Niu; Dong-Sheng Rui; Shu-Xia Guo
Journal:  Int J Environ Res Public Health       Date:  2016-04-16       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.